Gynaecological cancer treatment begins with identifying where the cancer started, what the biopsy shows, and how far it has spread. Selected early cervical cancers can be treated with surgery, while locally advanced cervical cancer usually needs chemotherapy and radiation, including brachytherapy. In advanced ovarian cancer, the main decision is often whether surgery or chemotherapy should come first. For endometrial cancer, which starts in the lining of the uterus, surgery is often the first step, and the pathology and molecular results help determine what treatment is needed afterward. [1–5]
By Dr Raman Narang, Consultant Medical & Hemato-Oncologist, New Delhi
A diagnosis of “cancer of the uterus” can leave a family unsure whether the cancer started in the cervix or in the lining of the womb. That distinction can change the first treatment completely. If you are seeking gynaecological cancer treatment in Delhi, ask your team to write down the exact site, subtype, and stage before comparing treatment options.
1. What symptoms should prompt a gynaecological assessment?
Symptoms overlap, but the pattern can help guide the first examination or test. [1, 2, 4]
| Symptom pattern | What it may lead the team to assess |
|---|---|
| Bleeding after sex, bleeding between periods, or persistent watery or blood-stained discharge | The cervix, usually starting with a pelvic examination. |
| Persistent bloating, pelvic or abdominal pain, feeling full after a small meal, or frequent urination | The ovaries and other possible causes, depending on the examination and symptom pattern. |
| Bleeding or spotting after menopause | The cervix and the lining of the uterus. Even a single episode deserves assessment. |
These symptoms can have causes other than cancer. Tell your doctor when they started, how often they occur, and whether they are getting worse. If bleeding is heavy or accompanied by dizziness or fainting, seek urgent medical care.
Screening and symptom evaluation serve different purposes. HPV testing and other cervical screening methods can detect risk or precancer before symptoms appear. Persistent bleeding or discharge needs assessment even after a recent normal screening result. CA-125 and pelvic ultrasound are used in selected diagnostic assessments. They are not recommended as routine ovarian cancer screening for average-risk women without symptoms. [1, 2]
2. How is cervical cancer diagnosed and treated?
The cervix is the lower part of the uterus that opens into the vagina. Persistent infection with high-risk human papillomavirus (HPV) causes most cervical cancers. The common subtypes are squamous cell carcinoma and adenocarcinoma. A biopsy confirms invasive cancer. Pelvic examination and imaging, often including pelvic MRI and, when indicated, CT or PET-CT, help assess tumour size, nearby tissue involvement, and lymph nodes. [1]
- Early cervical cancer. Surgery may be appropriate for selected patients. The extent of surgery and need for lymph node assessment depend on tumour size, depth, and other findings. For carefully selected patients with a small early tumour, a specialist may discuss fertility-sparing treatment before surgery.
- Locally advanced cervical cancer. Treatment with the aim of cure usually involves external-beam radiation and concurrent chemotherapy, commonly cisplatin when suitable, followed by or integrated with brachytherapy. Brachytherapy places the radiation source close to the tumour. It is a core part of definitive treatment, so ask early where and when it will be delivered. For eligible patients in certain high-risk settings, pembrolizumab may be added to chemoradiation. The indication depends on the stage and applicable prescribing criteria.
- Recurrent or metastatic cervical cancer. The team first assesses whether a recurrence can still be treated locally. If medicines are the main treatment, options may include platinum-based chemotherapy, bevacizumab, or immunotherapy in eligible patients. PD-L1 testing can guide immunotherapy in specific recurrent or metastatic settings. Previous pelvic radiation and current symptoms can also affect the choice. [1, 6]
3. How is ovarian cancer treated, and when does chemotherapy come first?
Epithelial ovarian cancer is the most common group. It includes high-grade serous, low-grade serous, clear-cell, endometrioid, and mucinous cancers. High-grade serous cancers of the ovary, fallopian tube, and primary peritoneum are generally treated along the same pathway. Pelvic ultrasound, CA-125, and staging scans can help assess a suspicious mass. Pathology establishes the diagnosis and subtype. [2, 3]
| Clinical situation | What the team usually discusses |
|---|---|
| A suspicious mass that appears confined to the ovary | Surgery and staging first. The final subtype, grade, and stage help determine whether follow-up alone or postoperative chemotherapy is appropriate. |
| Advanced epithelial cancer with a high likelihood of removing all visible disease safely | Upfront cytoreductive surgery, followed by chemotherapy. |
| Advanced disease unlikely to be completely removed at diagnosis, or a high immediate surgical risk | Tissue confirmation followed by chemotherapy first, usually carboplatin and paclitaxel, and reassessment for interval surgery. |
| Response to first-line platinum chemotherapy | Whether maintenance treatment is appropriate. The decision may involve BRCA1/2 and HRD results, prior treatment, side effects, and local access. |
If cancer returns, the team reviews the timing of recurrence, response to previous platinum treatment, and any maintenance therapy already used. For selected patients, additional biomarker testing may identify a treatment option, such as folate receptor alpha testing in certain platinum-resistant cancers. [2, 3, 5]
Ovarian germ cell tumours
Dysgerminoma, yolk sac tumour, immature teratoma, and mixed germ cell tumours are malignant ovarian germ cell tumours that often occur in adolescents and young adults. AFP, beta-hCG, and LDH can help assess a suspected tumour and monitor treatment when elevated at diagnosis. Surgery can often preserve the uterus and the other ovary. After adequate surgical staging, selected patients with stage IA dysgerminoma or stage IA grade 1 immature teratoma may be monitored closely. Many patients with higher-risk disease need cisplatin-based chemotherapy, commonly BEP. Fertility goals should be discussed before surgery when feasible. [7]
4. How is uterine or endometrial cancer diagnosed and treated?
Endometrial cancer starts in the lining of the uterus. Uterine sarcomas start in the muscle or supporting tissues and follow a different treatment pathway. For suspected endometrial cancer, a transvaginal ultrasound may be part of the initial assessment. A sample of the uterine lining, obtained by endometrial biopsy or hysteroscopy and sampling, is used to establish the diagnosis. Persistent or recurrent bleeding may need further evaluation even after an initially reassuring assessment. [4]
For most patients with operable endometrial cancer, treatment starts with hysterectomy, usually with removal of the fallopian tubes and ovaries. Sentinel lymph node mapping may be used when lymph node staging is appropriate. The final pathology assesses tumour type and grade, depth of invasion into the uterine muscle, and whether cancer cells are present in lymphatic or blood vessels. [4]
- Early, low-risk disease. Surgery alone is often sufficient.
- Higher-risk disease. The team may consider vaginal brachytherapy, pelvic radiation, chemotherapy, or a combination. The choice depends on where the risk of recurrence is greatest and on the tumour’s molecular classification.
- Advanced or recurrent disease. Depending on the subtype, prior treatments, and sites of spread, options can include chemotherapy with immunotherapy, radiation for selected sites, or hormone therapy for selected slow-growing, hormone receptor–positive tumours. [4]
Molecular testing can change the plan. Endometrial cancers may be classified as POLE-mutated, mismatch repair deficient (dMMR), p53-abnormal, or no specific molecular profile (NSMP). These groups help estimate recurrence risk and guide discussions about treatment after surgery. A dMMR result can also influence immunotherapy choices in advanced disease and may prompt evaluation for Lynch syndrome. [4]
What I look for clinically before recommending treatment
I start by confirming the primary site and biopsy subtype. In locally advanced cervical cancer, I check that the radiation plan includes brachytherapy. In advanced ovarian cancer, I ask where the disease is and whether the surgical team expects to remove all visible tumour safely. After endometrial cancer surgery, I review the pathology and molecular results together to understand whether additional treatment would meaningfully lower the risk of recurrence. I also ask early about fertility, menopause, and sexual health, because these concerns can influence treatment decisions and recovery.
How the next step is decided
| If the reports show… | The next discussion is about… |
|---|---|
| A small, early cervical cancer | Surgery, lymph node assessment, and fertility preservation where appropriate |
| Locally advanced cervical cancer | Chemoradiation, brachytherapy, and eligibility for additional systemic treatment |
| Advanced epithelial ovarian cancer | Whether all visible disease can be removed safely now or chemotherapy should come first |
| A suspected ovarian germ cell tumour | Tumour markers, specialist pathology, and fertility-sparing surgery where feasible |
| Endometrial cancer after surgery | Whether stage, pathology, and molecular results support follow-up alone or additional treatment |
What to bring to a gynaecological cancer consultation in Delhi
- Biopsy or surgical pathology report and details for obtaining the slides or tissue block.
- Pelvic ultrasound, MRI, CT, or PET-CT reports, with original images if available.
- Operation notes, including whether visible disease remained after ovarian cancer surgery.
- Dated CA-125 or germ cell tumour marker results, if performed.
- BRCA, HRD, MMR/MSI, POLE, p53, or PD-L1 reports, as applicable.
- Records of previous chemotherapy, radiation, or brachytherapy, plus any fertility priorities and relevant family history.
Frequently asked questions
Are cervical cancer and uterine cancer the same?
Cervical cancer begins in the cervix. When a report says endometrial cancer, it means the cancer started in the lining of the main body of the uterus. The site determines which staging and treatment pathway applies. [1, 4]
Does a high CA-125 confirm ovarian cancer?
CA-125 can rise for several reasons, including benign conditions. The team interprets it alongside the examination and imaging. Pathology confirms the diagnosis. [2, 3]
Can stage IV ovarian cancer still be treated with surgery?
Surgery can be part of the plan for selected patients. The team considers where the cancer has spread, whether all visible disease can be removed safely, and whether chemotherapy should come first. [3]
Does everyone need radiation after surgery for endometrial cancer?
Many patients with low-risk disease can be followed after surgery alone. For higher-risk disease, the team considers radiation or other treatment based on the final stage, pathology, and molecular results. [4]
Before treatment starts, ask which finding determines the first step and what would change the plan. If surgery, chemotherapy, and radiation are all being discussed, ask your team to explain the purpose and sequence of each treatment.
This page is for general education. Individual treatment decisions require review of your pathology, scans, symptoms, and overall health by your treating team.
Clinical references
- National Cancer Institute. Cervical Cancer Treatment (PDQ). Health Professional Version.
- National Cancer Institute. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)and Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Screening (PDQ).
- American Society of Clinical Oncology. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. 2025.
- ESGO–ESTRO–ESP. Guidelines for the Management of Patients With Endometrial Carcinoma. 2025 update.
- European Society for Medical Oncology. Clinical Practice Guideline Express Update on the Management of Epithelial Ovarian Cancer. 2026.
- US Food and Drug Administration. Approval of Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer.
- National Cancer Institute. Ovarian Germ Cell Tumors Treatment (PDQ). Health Professional Version.
WordPress and Rank Math settings
| Field | Suggested setting |
|---|---|
| SEO title | Gynaecological Cancer Treatment in Delhi | Dr Raman Narang |
| Meta description | Learn how cervical, ovarian and uterine cancers are diagnosed and treated in Delhi, including surgery, chemotherapy, radiation and biomarker testing. |
| Slug | gynaecological-cancer-treatment-delhi |
| Primary keyword | gynaecological cancer treatment in Delhi |
| Secondary keywords | gynecological cancer treatment in Delhi, cervical cancer treatment in Delhi, ovarian cancer treatment in Delhi, uterine cancer treatment in Delhi, endometrial cancer treatment in Delhi, brachytherapy for cervical cancer, chemotherapy before ovarian cancer surgery |
| Search intent | Patients and families comparing treatment pathways after a gynaecological cancer diagnosis or preparing for a second opinion in Delhi |
| Internal-link anchor suggestions | Ovarian cancer treatment in Delhi, Well Woman Conversations, hereditary breast and ovarian cancer risk, cancer treatment second opinion |
| Page and schema | Use this as the main gynaecological cancer treatment page, with your ovarian cancer page as a detailed companion. Use MedicalWebPage for the permanent treatment page or BlogPosting if published as an article. Include your physician profile, clinical review date, and breadcrumbs. Keep the FAQs visible. |
| Visual brief | Use a medically reviewed pelvic anatomy diagram labelling the cervix, uterine lining, fallopian tubes, and ovaries. Suggested alt text is “Where cervical, endometrial and ovarian cancers begin.” |